BioSpace News Archive

BioMidwest

10 Reasons to Keep an Eye on Chicago Biotech in 2023

Between top-notch academic institutions, solid venture capital funding, expanding lab space and governmental support, Chicago is emerging as a true hotbed for biotech growth.

October 18, 2022
·
5 min read
·
Lisa Munger
Business

GSK Expands AI Footprint with $70M Tempus Deal - Updated

GlaxoSmithKline (GSK) announced Tuesday morning it has struck a $70 million deal with Tempus in exchange for expanded access to Tempus’ AI-based patient data platform.

October 18, 2022
·
2 min read
·
Rosemary Scott
Business

Mereo Cuts 40% of Staff to Drive Rare Disease Programs though the Clinic (Updated)

Mereo BioPharma will cut 40% of its headcount and significantly reduce expenses to support the advancement of its lead programs through the clinic.

October 18, 2022
·
2 min read
·
Alex Keown
Surface, Immutep and Corbus Move Beyond Anti-PD-1/PD-LI with New Targets

PD-L1 expression is not the static, “yes/no” predictor of tumor response for which researchers hoped. Surface Oncology, Immutep and Corbus are each taking a different approach to immuno-oncology.

October 18, 2022
·
5 min read
·
Gail Dutton
Editas Rumored to be in “Advanced Discussions” around Potential Sale of Oncology Assets

Editas is reportedly in “advanced discussions” regarding the sale of its preclinical cancer lineup. The company told BioSpace it has undertaken a strategic review to inform opportunities.

October 18, 2022
·
2 min read
·
Heather McKenzie
Drug Development

Roche Scraps Mid-Phase Programs in Hepatitis B, Geographic Atrophy

As part of its third-quarter report, Roche announced it has cut two Phase II programs, one for hepatitis B and the other for geographic atrophy, a form of eye disease.

October 18, 2022
·
2 min read
·
Mark Terry
Deals

Lilly Continues Foray into Gene Therapies with $487M Akouos Buyout

Eli Lilly is acquiring precision medicine biotech Akouos for $487 million in cash in a deal focused on developing gene therapies for hearing loss.

October 18, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Salarius Stock Plunges 27% After Death in Sarcoma Trial

Salarius Pharmaceuticals voluntarily paused enrollment of its Phase I/II trial of seclidemstat for Ewing sarcoma and FET-rearranged sarcomas after a patient’s death.

October 18, 2022
·
2 min read
·
Mark Terry
Business

AstraZeneca, Ikena Team Up Against EGFR-mutated NSCLC - Updated

Ikena Oncology and AstraZeneca have entered into an agreement to evaluate Tagrisso (osimertinib) with Ikena’s IK-930 in EGFR-mutated non-small cell lung cancer.

October 18, 2022
·
3 min read
·
Kaley Lefevre
Business

Empyrean Grabs $22M to Target CNS Disorders with Plant-Based Platform

Genetic engineering company Empyrean Neurosciences stepped into the CNS arena with $22 million and a small molecule platform derived from plants and fungi.

October 18, 2022
·
3 min read
·
Alex Keown